CHEMOCENTRYX, INC.
Patent Owner
Stats
- 109 US PATENTS IN FORCE
- 4 US APPLICATIONS PENDING
- Mar 15, 2018 most recent publication
Details
- 109 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 2,493 Total Citation Count
- Aug 25, 2000 Earliest Filing
- 50 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2018/0029,986 POLYMORPHIC FORMS OF THE SODIUM SALT OF 4-TERT- BUTYL -N-[4-CHLORO-2-(1-OXY-PYRIDINE-4-CARBONYL)-PHENYL]-BENZENE SULFONAMIDESep 29, 17Feb 01, 18[A61K, C07D]
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2017/0327,508 DEUTERATED HETEROARYL SULFONAMIDES AND THEIR USEAbandonedMay 16, 17Nov 16, 17[C07D, C07B]
2011/0165,164 COMPOSITIONS AND METHODS FOR DETECTING AND TREATING DISEASES AND CONDITIONS RELATED TO CHEMOKINE RECEPTORSAbandonedDec 09, 10Jul 07, 11[A61K, C12Q, G01N, A61P]
2011/0052,589 COMPOSITIONS AND METHODS FOR DETECTING AND TREATING DISEASES AND CONDITIONS RELATED TO CHEMOKINE RECEPTORSAbandonedJun 11, 10Mar 03, 11[A61K, G01N, A61P]
2010/0278,820 REAGENTS THAT BIND CCX-CKR2AbandonedJan 21, 10Nov 04, 10[A61K, C07H, C12P, G01N, A61P, C07K]
2010/0247,540 Methods and Compositions For Modulating AngiogenesisAbandonedJul 20, 09Sep 30, 10[A61K, A61P]
2010/0144,720 INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2AbandonedDec 11, 09Jun 10, 10[A61K, C07D, C12N, C07C, A61P]
2010/0113,472 COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS AND CANCERSAbandonedNov 03, 09May 06, 10[A61K, A61P]
2009/0252,779 AZAINDAZOLE COMPOUNDS AND METHODS OF USEAbandonedApr 03, 09Oct 08, 09[A61K, A61F, C07D]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.